View Item 

Show simple item record

Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials

dc.contributor.authorVakil, Nimishen_US
dc.contributor.authorLaine, Lorenen_US
dc.contributor.authorTalley, Nicholas J.en_US
dc.contributor.authorZakko, Salam F.en_US
dc.contributor.authorTack, Janen_US
dc.contributor.authorChey, William D.en_US
dc.contributor.authorKralstein, Jeffreyen_US
dc.contributor.authorEarnest, David L.en_US
dc.contributor.authorLigozio, Gregoryen_US
dc.contributor.authorCohard-Radice, Marielleen_US
dc.date.accessioned2010-06-01T21:35:17Z
dc.date.available2010-06-01T21:35:17Z
dc.date.issued2008-08en_US
dc.identifier.citationVakil, Nimish; Laine, Loren; Talley, Nicholas J.; Zakko, Salam F.; Tack, Jan; Chey, William D.; Kralstein, Jeffrey; Earnest, David L.; Ligozio, Gregory; Cohard-Radice, Marielle (2008). "Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials." The American Journal of Gastroenterology 103(8): 1906-1919. <http://hdl.handle.net/2027.42/74639>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74639
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18616658&dopt=citationen_US
dc.format.extent382196 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2008 American College of Gastroenterology/Blackwell Publishingen_US
dc.titleTegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trialsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherUniversity of Wisconsin School of Medicine and Public Health, Madison, Wisconsin and Marquette University College of Health Sciences, Milwaukee, Wisconsinen_US
dc.contributor.affiliationotherUniversity of Southern California, Los Angeles, Californiaen_US
dc.contributor.affiliationotherMayo Clinic College of Medicine, Rochester, Minnesotaen_US
dc.contributor.affiliationotherConnecticut Gastroenterology Institute, Bristol, Connecticuten_US
dc.contributor.affiliationotherUniversity of Leuven, Leuven, Belgiumen_US
dc.contributor.affiliationotherNovartis Pharmaceuticals Corporation, East Hanover, New Jerseyen_US
dc.identifier.pmid18616658en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74639/1/j.1572-0241.2008.01953.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2008.01953.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceEl-Serag HB, Talley NJ. Systemic review: The prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 643 – 54.en_US
dc.identifier.citedreferenceDrossman DA, Corazziari E, Talley NJ, et al. Rome II: The functional gastrointestinal disorders. McLean, VA: Degnon Associates, 2000.en_US
dc.identifier.citedreferenceThomson ABR, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481 – 91.en_US
dc.identifier.citedreferenceTack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466 – 79.en_US
dc.identifier.citedreferenceEl-Serag HB, Talley NJ. Systematic review: Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 387 – 93.en_US
dc.identifier.citedreferenceTalley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 584 – 9.en_US
dc.identifier.citedreferenceChoung RS, Talley NJ. Novel mechanisms in functional dyspepsia. World J Gastroenterol 2006; 12: 673 – 7.en_US
dc.identifier.citedreferenceKindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006; 55: 1681 – 91.en_US
dc.identifier.citedreferenceQuigley E. Review article: Gastric emptying in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20: 56 – 60.en_US
dc.identifier.citedreferenceTack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239 – 55.en_US
dc.identifier.citedreferenceSarnelli G, Caenepeel P, Geypens B, et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003; 98: 783 – 8.en_US
dc.identifier.citedreferenceTalley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756 – 80.en_US
dc.identifier.citedreferenceTalley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100: 2324 – 37.en_US
dc.identifier.citedreferencePeura DA, Kovacs TO, Metz DC, et al. Lansoprazole in the treatment of functional dyspepsia: Two double-blind, randomized, placebo-controlled trials. Am J Med 2004; 116: 740 – 8.en_US
dc.identifier.citedreferenceWong WM, Wong BC, Hung WK, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 502 – 6.en_US
dc.identifier.citedreferenceTalley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055 – 65.en_US
dc.identifier.citedreferenceJohanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004; 2: 796 – 805.en_US
dc.identifier.citedreferenceKamm MA, MÜller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005; 100: 362 – 72.en_US
dc.identifier.citedreferenceMÜller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655 – 66.en_US
dc.identifier.citedreferenceNovick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877 – 88.en_US
dc.identifier.citedreferenceTack J, MÜller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut 2005; 54: 1707 – 13.en_US
dc.identifier.citedreferenceTougas G, Cheng Y, Luo D, et al. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology 2003; 124 ( Suppl 2 ): A54.en_US
dc.identifier.citedreferenceVan Der Voort IR, Schmidtmann M, Fach K, et al. Tegaserod improves gastric emptying and alters myocardial activity in dyspeptic patients. Gastroenterology 2004; 126 ( Suppl 2 ): A643.en_US
dc.identifier.citedreferenceTalley N, Tack J, d'Elia T, et al. Tegaserod, a partial 5-HT4 agonist, in functional dyspepsia patients with normal gastric emptying: A randomized, double-blind, placebo-controlled trial. Gut 2002; 51: A193.en_US
dc.identifier.citedreferenceNasra I, Ashok A, Summers R, et al. Effect of tegaserod on antroduodenal and jejunal motility. Gastroenterology 2006; 130 ( Suppl 2 ): A743.en_US
dc.identifier.citedreferenceThumshirn M, Fruehauf H, Stutz B, et al. Effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia and healthy controls. Gastroenterology 2005; 128 ( Suppl 2 ): A469.en_US
dc.identifier.citedreferenceTack J, Vos R, Tougas G, et al. Effect of tegaserod, a 5-HT4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia. Gastroenterology 2005; 128 ( Suppl 2 ): A94.en_US
dc.identifier.citedreferenceCoffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577 – 85.en_US
dc.identifier.citedreferenceSabate J, Bouhassira D, Poupardin C, et al. Antinociceptive effect of tegaserod in female IBS constipated patients. Gastroenterology 2005; 128 ( Suppl 2 ): A - 468.en_US
dc.identifier.citedreferenceTack J, Delia T, Ligozio G, et al. A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) with normal gastric emptying (NGE). Gastroenterology 2002; 122 ( Suppl 2 ): A - 20.en_US
dc.identifier.citedreferenceVakil N, Van Zanten SV, Chang L, et al. Comprehension and awareness of symptoms in women with dyspepsia. Aliment Pharmacol Ther 2005; 22: 1147 – 55.en_US
dc.identifier.citedreferenceTalley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: Responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther 2001; 15: 207 – 16.en_US
dc.identifier.citedreferenceTalley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: A United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 1999; 94: 2390 – 7.en_US
dc.identifier.citedreferenceO'Donnell LJD, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439 – 40.en_US
dc.identifier.citedreferenceSturm A, Holtmann G, Goebell H, et al. Prokinetics in patients with gastroparesis: A systematic analysis. Digestion 1999; 60: 422 – 7.en_US
dc.identifier.citedreferenceBolling-Sternevald E, Lauritsen K, Talley NJ, et al. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 2003; 18: 117 – 24.en_US
dc.identifier.citedreferenceTalley NJ. American Gastroenterological Association medical position statement: Evaluation of dyspepsia. Gastroenterology 2005; 129: 1753 – 5.en_US
dc.identifier.citedreferenceTalley NJ, Vakil N, Ballard ED, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 1106 – 11.en_US
dc.identifier.citedreferenceTalley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up. The optimal regimen cures helicobacter induced dyspepsia (ORCHID) study group. BMJ 1999; 318: 833 – 7.en_US
dc.identifier.citedreferenceTalley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: The BOND, OPERA, PILOT, and ENCORE studies. Gut 2002; 50: iv36–41.en_US
dc.identifier.citedreferenceVan PB, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006; 3: CD002095.en_US
dc.identifier.citedreferenceMoayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; CD001960.en_US
dc.identifier.citedreferenceTalley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: A randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 1653 – 61.en_US
dc.identifier.citedreferenceChoung RS, Talley NJ, Peterson J, et al. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil 2007; 19: 180 – 7.en_US
dc.identifier.citedreferenceAkyuz F, Mimidis K, Mikolai H, et al. Influence of itopride and domperidone on gastric tone and on the perception of gastric distention in healthy subjects. Gastroenterology 2007; 132 ( Suppl 2 ): A688.en_US
dc.identifier.citedreferenceHoltmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 832 – 40.en_US
dc.identifier.citedreferenceTalley NJ, Tack J, Ptak T, et al. Efficacy and safety of itopride in functional dyspepsia: Results of two phase III multicentre, randomized, double-blind, placebo-controlled trials. Gastroenterology 2007; 132 ( Suppl 2 ): A93.en_US
dc.identifier.citedreference48.  Food and Drug Administration. Patient-reported outcome measures: Use in medical product development to support labeling claims 2007. Available at: http://www. fda.gov/cber/gdlns/prolbl.htm. Accessed August 12, 2007.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2008.01953.x.pdf
Size:
373.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.